Aerpio Announces Enrollment Completed in the 28-Day Phase 2 Razuprotafib Glaucoma Trial - Seite 3

These forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents the Company files with the SEC available at www.sec.gov.

Contacts

Investors & Media:
Aerpio Pharmaceuticals, Inc.
Joseph Gardner
President & Founder
[e-mail]

Gina Marek
VP Finance
[e-mail]

Or

Investors:
Irina Koffler
LifeSci Advisors
[e-mail]

Source: Aerpio Pharmaceuticals, Inc.